480 related articles for article (PubMed ID: 24260500)
21. Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.
Peng DH; Rodriguez BL; Diao L; Gaudreau PO; Padhye A; Konen JM; Ochieng JK; Class CA; Fradette JJ; Gibson L; Chen L; Wang J; Byers LA; Gibbons DL
Nat Commun; 2021 May; 12(1):2606. PubMed ID: 33972557
[TBL] [Abstract][Full Text] [Related]
22. Nitrilase 1 modulates lung tumor progression in vitro and in vivo.
Wang YA; Sun Y; Le Blanc JM; Solomides C; Zhan T; Lu B
Oncotarget; 2016 Apr; 7(16):21381-92. PubMed ID: 26967383
[TBL] [Abstract][Full Text] [Related]
23. Endoplasmic reticulum chaperone GRP78/BiP is critical for mutant Kras-driven lung tumorigenesis.
Rangel DF; Dubeau L; Park R; Chan P; Ha DP; Pulido MA; Mullen DJ; Vorobyova I; Zhou B; Borok Z; Offringa IA; Lee AS
Oncogene; 2021 May; 40(20):3624-3632. PubMed ID: 33931739
[TBL] [Abstract][Full Text] [Related]
24. Vaginal Squamous Cell Carcinoma Develops in Mice with Conditional Arid1a Loss and Gain of Oncogenic Kras Driven by Progesterone Receptor Cre.
Wang X; Praça MSL; Wendel JRH; Emerson RE; DeMayo FJ; Lydon JP; Hawkins SM
Am J Pathol; 2021 Jul; 191(7):1281-1291. PubMed ID: 33882289
[TBL] [Abstract][Full Text] [Related]
25. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.
Kasinski AL; Slack FJ
Cancer Res; 2012 Nov; 72(21):5576-87. PubMed ID: 22964582
[TBL] [Abstract][Full Text] [Related]
26. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis.
Grabner B; Schramek D; Mueller KM; Moll HP; Svinka J; Hoffmann T; Bauer E; Blaas L; Hruschka N; Zboray K; Stiedl P; Nivarthi H; Bogner E; Gruber W; Mohr T; Zwick RH; Kenner L; Poli V; Aberger F; Stoiber D; Egger G; Esterbauer H; Zuber J; Moriggl R; Eferl R; Győrffy B; Penninger JM; Popper H; Casanova E
Nat Commun; 2015 Mar; 6():6285. PubMed ID: 25734337
[TBL] [Abstract][Full Text] [Related]
27. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
28. Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.).
Wang IC; Ustiyan V; Zhang Y; Cai Y; Kalin TV; Kalinichenko VV
Oncogene; 2014 Nov; 33(46):5391-6. PubMed ID: 24213573
[TBL] [Abstract][Full Text] [Related]
29. Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with
Drilon A; Schoenfeld AJ; Arbour KC; Litvak A; Ni A; Montecalvo J; Yu HA; Panora E; Ahn L; Kennedy M; Haughney-Siller A; Miller V; Ginsberg M; Ladanyi M; Arcila M; Rekhtman N; Kris MG; Riely GJ
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30936194
[No Abstract] [Full Text] [Related]
30. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
31. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
[TBL] [Abstract][Full Text] [Related]
32. Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.
Zhu X; Zhao L; Park JW; Willingham MC; Cheng SY
Neoplasia; 2014 Sep; 16(9):757-69. PubMed ID: 25246276
[TBL] [Abstract][Full Text] [Related]
33. Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma.
Wang Y; Hou N; Cheng X; Zhang J; Tan X; Zhang C; Tang Y; Teng Y; Yang X
Int J Biol Sci; 2017; 13(5):652-659. PubMed ID: 28539837
[TBL] [Abstract][Full Text] [Related]
34. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.
Elsum IA; Yates LL; Pearson HB; Phesse TJ; Long F; O'Donoghue R; Ernst M; Cullinane C; Humbert PO
Oncogene; 2014 Nov; 33(48):5523-33. PubMed ID: 24276238
[TBL] [Abstract][Full Text] [Related]
35. PKC
Garg R; Cooke M; Benavides F; Abba MC; Cicchini M; Feldser DM; Kazanietz MG
Cancer Res; 2020 Dec; 80(23):5166-5173. PubMed ID: 32994205
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors.
Bhatt V; Lan T; Wang W; Kong J; Lopes EC; Wang J; Khayati K; Raju A; Rangel M; Lopez E; Hu ZS; Luo X; Su X; Malhotra J; Hu W; Pine SR; White E; Guo JY
Cell Death Dis; 2023 Jan; 14(1):61. PubMed ID: 36702816
[TBL] [Abstract][Full Text] [Related]
37. STAT3 is Activated by CTGF-mediated Tumor-stroma Cross Talk to Promote HCC Progression.
Makino Y; Hikita H; Kato S; Sugiyama M; Shigekawa M; Sakamoto T; Sasaki Y; Murai K; Sakane S; Kodama T; Sakamori R; Kobayashi S; Eguchi H; Takemura N; Kokudo N; Yokoi H; Mukoyama M; Tatsumi T; Takehara T
Cell Mol Gastroenterol Hepatol; 2023; 15(1):99-119. PubMed ID: 36210625
[TBL] [Abstract][Full Text] [Related]
38. USP5-Beclin 1 axis overrides p53-dependent senescence and drives Kras-induced tumorigenicity.
Li J; Wang Y; Luo Y; Liu Y; Yi Y; Li J; Pan Y; Li W; You W; Hu Q; Zhao Z; Zhang Y; Cao Y; Zhang L; Yuan J; Xiao ZJ
Nat Commun; 2022 Dec; 13(1):7799. PubMed ID: 36528652
[TBL] [Abstract][Full Text] [Related]
39. Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis.
Hill KS; Erdogan E; Khoor A; Walsh MP; Leitges M; Murray NR; Fields AP
Oncogene; 2014 Apr; 33(16):2134-44. PubMed ID: 23604119
[TBL] [Abstract][Full Text] [Related]
40. Mig-6 deficiency cooperates with oncogenic Kras to promote mouse lung tumorigenesis.
Liu J; Cho SN; Wu SP; Jin N; Moghaddam SJ; Gilbert JL; Wistuba I; DeMayo FJ
Lung Cancer; 2017 Oct; 112():47-56. PubMed ID: 29191600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
